Marc Iglarz
- Optimization of tissue targeting properties of macitentan, a new dual endothelin receptor antagonist, improves its efficacy in a rat model of pulmonary fibrosis associated with pulmonary arterial hypertensionBy Marc Iglarz, Kyle Landskroner, Daniel Wanner, Markus Rey, Patrick Hess and Martine ClozelMarc IglarzPharmacology and Preclinical Development, Actelion Pharmaceuticals Ltd., Allschwil, SwitzerlandKyle LandskronerPharmacology and Preclinical Development, Actelion Pharmaceuticals Ltd., Allschwil, SwitzerlandDaniel WannerPharmacology and Preclinical Development, Actelion Pharmaceuticals Ltd., Allschwil, SwitzerlandMarkus ReyPharmacology and Preclinical Development, Actelion Pharmaceuticals Ltd., Allschwil, SwitzerlandPatrick HessPharmacology and Preclinical Development, Actelion Pharmaceuticals Ltd., Allschwil, SwitzerlandMartine ClozelPharmacology and Preclinical Development, Actelion Pharmaceuticals Ltd., Allschwil, Switzerland
- Vasopressin is involved in endothelin receptor antagonist-induced fluid retention in rat. Differential effect of selective ETA and dual ETA/ETB receptor antagonistsBy Magali Vercauteren, Daniel Strasser, Enrico Vezzali, Anna Stalder, Marc Iglarz, Patrick Hess and Martine ClozelMagali Vercauteren1Drug Discovery, Actelion Pharmaceuticals Ltd., Allschwil, SwitzerlandDaniel Strasser1Drug Discovery, Actelion Pharmaceuticals Ltd., Allschwil, SwitzerlandEnrico Vezzali1Drug Discovery, Actelion Pharmaceuticals Ltd., Allschwil, SwitzerlandAnna Stalder1Drug Discovery, Actelion Pharmaceuticals Ltd., Allschwil, SwitzerlandMarc Iglarz1Drug Discovery, Actelion Pharmaceuticals Ltd., Allschwil, SwitzerlandPatrick Hess1Drug Discovery, Actelion Pharmaceuticals Ltd., Allschwil, SwitzerlandMartine Clozel1Drug Discovery, Actelion Pharmaceuticals Ltd., Allschwil, Switzerland
- Unique receptor dissociation kinetics of the novel endothelin receptor antagonist macitentanBy John Gatfield, Celia Mueller Grandjean, Thomas Sasse, Beat Steiner, Pauline Steiner, Marc Iglarz, Katalin Kauser, Martine Clozel and Oliver NaylerJohn Gatfield1Drug Discovery, Actelion Pharmaceuticals Ltd, Allschwil, SwitzerlandCelia Mueller Grandjean1Drug Discovery, Actelion Pharmaceuticals Ltd, Allschwil, SwitzerlandThomas Sasse1Drug Discovery, Actelion Pharmaceuticals Ltd, Allschwil, SwitzerlandBeat Steiner1Drug Discovery, Actelion Pharmaceuticals Ltd, Allschwil, SwitzerlandPauline Steiner1Drug Discovery, Actelion Pharmaceuticals Ltd, Allschwil, SwitzerlandMarc Iglarz1Drug Discovery, Actelion Pharmaceuticals Ltd, Allschwil, SwitzerlandKatalin Kauser1Drug Discovery, Actelion Pharmaceuticals Ltd, Allschwil, SwitzerlandMartine Clozel1Drug Discovery, Actelion Pharmaceuticals Ltd, Allschwil, SwitzerlandOliver Nayler1Drug Discovery, Actelion Pharmaceuticals Ltd, Allschwil, Switzerland
- Superior in vivo efficacy of macitentan: Comparison to other endothelin receptor antagonistsBy Marc Iglarz, Markus Rey, Patrick Hess, Katalin Kauser and Martine ClozelMarc Iglarz1Drug Discovery, Actelion Pharmaceuticals Ltd., Allschwil, SwitzerlandMarkus Rey1Drug Discovery, Actelion Pharmaceuticals Ltd., Allschwil, SwitzerlandPatrick Hess1Drug Discovery, Actelion Pharmaceuticals Ltd., Allschwil, SwitzerlandKatalin Kauser1Drug Discovery, Actelion Pharmaceuticals Ltd., Allschwil, SwitzerlandMartine Clozel1Drug Discovery, Actelion Pharmaceuticals Ltd., Allschwil, Switzerland
- A novel and translatable cell assay for the study of vascular signalling in pulmonary hypertensionBy Daniel M. Reed, Peter M. George, Catherine Francis, Laura B. Feyereisen, William Swain, Marc Iglarz, Amanda Wan, Benjamin Garfield, John Wort and Jane A. MitchellDaniel M. Reed1Dept. of Cardiothoracic Pharmacology, NHLI, Imperial College London, London, United KingdomPeter M. George1Dept. of Cardiothoracic Pharmacology, NHLI, Imperial College London, London, United KingdomCatherine Francis1Dept. of Cardiothoracic Pharmacology, NHLI, Imperial College London, London, United KingdomLaura B. Feyereisen1Dept. of Cardiothoracic Pharmacology, NHLI, Imperial College London, London, United KingdomWilliam Swain2Actelion Pharmaceuticals UK, Actelion, London, United KingdomMarc Iglarz2Actelion Pharmaceuticals UK, Actelion, London, United KingdomAmanda Wan2Actelion Pharmaceuticals UK, Actelion, London, United KingdomBenjamin Garfield1Dept. of Cardiothoracic Pharmacology, NHLI, Imperial College London, London, United KingdomJohn Wort1Dept. of Cardiothoracic Pharmacology, NHLI, Imperial College London, London, United KingdomJane A. Mitchell1Dept. of Cardiothoracic Pharmacology, NHLI, Imperial College London, London, United Kingdom
- Chymase: a multifunctional player in pulmonary hypertension associated with lung fibrosisBy Djuro Kosanovic, Himal Luitel, Bhola Kumar Dahal, Teodora Cornitescu, Wiebke Janssen, A.H. Jan Danser, Ingrid M. Garrelds, Jo G.R. De Mey, Gregorio Fazzi, Paul Schiffers, Marc Iglarz, Walter Fischli, Hossein Ardeschir Ghofrani, Norbert Weissmann, Friedrich Grimminger, Werner Seeger, Irwin Reiss and Ralph Theo SchermulyArticle | Published in 2015 in European Respiratory JournalDjuro Kosanovic1Universities of Giessen and Marburg Lung Center (UGMLC), Member of the German Center for Lung Research, Giessen, Germany2Division of Neonatology, Erasmus MC Sophia Children's Hospital, Rotterdam, The NetherlandsHimal Luitel1Universities of Giessen and Marburg Lung Center (UGMLC), Member of the German Center for Lung Research, Giessen, GermanyBhola Kumar Dahal1Universities of Giessen and Marburg Lung Center (UGMLC), Member of the German Center for Lung Research, Giessen, Germany3Risk Factor Modification Centre (RFMC), St. Michael's Hospital, Toronto, ON, CanadaTeodora Cornitescu1Universities of Giessen and Marburg Lung Center (UGMLC), Member of the German Center for Lung Research, Giessen, GermanyWiebke Janssen1Universities of Giessen and Marburg Lung Center (UGMLC), Member of the German Center for Lung Research, Giessen, GermanyA.H. Jan Danser4Dept of Pharmacology, Erasmus University Rotterdam, Rotterdam, The NetherlandsIngrid M. Garrelds4Dept of Pharmacology, Erasmus University Rotterdam, Rotterdam, The NetherlandsJo G.R. De Mey5Dept of Cardiovascular and Renal Research, University of Southern Denmark, Odense, Denmark6Dept of Pharmacology, Maastricht University, Maastricht, The NetherlandsGregorio Fazzi6Dept of Pharmacology, Maastricht University, Maastricht, The NetherlandsPaul Schiffers6Dept of Pharmacology, Maastricht University, Maastricht, The NetherlandsMarc Iglarz7Actelion Pharmaceuticals Ltd, Allschwill, SwitzerlandWalter Fischli7Actelion Pharmaceuticals Ltd, Allschwill, SwitzerlandHossein Ardeschir Ghofrani1Universities of Giessen and Marburg Lung Center (UGMLC), Member of the German Center for Lung Research, Giessen, GermanyNorbert Weissmann1Universities of Giessen and Marburg Lung Center (UGMLC), Member of the German Center for Lung Research, Giessen, GermanyFriedrich Grimminger1Universities of Giessen and Marburg Lung Center (UGMLC), Member of the German Center for Lung Research, Giessen, GermanyWerner Seeger1Universities of Giessen and Marburg Lung Center (UGMLC), Member of the German Center for Lung Research, Giessen, Germany8Max-Planck-Institute for Heart and Lung Research, Member of the German Center for Lung Research, Bad Nauheim, GermanyIrwin Reiss2Division of Neonatology, Erasmus MC Sophia Children's Hospital, Rotterdam, The Netherlands9Both authors contributed equallyRalph Theo Schermuly1Universities of Giessen and Marburg Lung Center (UGMLC), Member of the German Center for Lung Research, Giessen, Germany9Both authors contributed equally
- Chymase: a multifunctional player in pulmonary hypertension associated with lung fibrosisBy Djuro Kosanovic, Himal Luitel, Bhola Kumar Dahal, Teodora Cornitescu, Wiebke Janssen, A.H. Jan Danser, Ingrid M. Garrelds, Jo G.R. De Mey, Gregorio Fazzi, Paul Schiffers, Marc Iglarz, Walter Fischli, Hossein Ardeschir Ghofrani, Norbert Weissmann, Friedrich Grimminger, Werner Seeger, Irwin Reiss and Ralph Theo SchermulyDjuro Kosanovic1Universities of Giessen and Marburg Lung Center (UGMLC), Member of the German Center for Lung Research, Giessen, Germany2Division of Neonatology, Erasmus MC Sophia Children's Hospital, Rotterdam, The NetherlandsHimal Luitel1Universities of Giessen and Marburg Lung Center (UGMLC), Member of the German Center for Lung Research, Giessen, GermanyBhola Kumar Dahal1Universities of Giessen and Marburg Lung Center (UGMLC), Member of the German Center for Lung Research, Giessen, Germany3Risk Factor Modification Centre (RFMC), St. Michael's Hospital, Toronto, ON, CanadaTeodora Cornitescu1Universities of Giessen and Marburg Lung Center (UGMLC), Member of the German Center for Lung Research, Giessen, GermanyWiebke Janssen1Universities of Giessen and Marburg Lung Center (UGMLC), Member of the German Center for Lung Research, Giessen, GermanyA.H. Jan Danser4Dept of Pharmacology, Erasmus University Rotterdam, Rotterdam, The NetherlandsIngrid M. Garrelds4Dept of Pharmacology, Erasmus University Rotterdam, Rotterdam, The NetherlandsJo G.R. De Mey5Dept of Cardiovascular and Renal Research, University of Southern Denmark, Odense, Denmark6Dept of Pharmacology, Maastricht University, Maastricht, The NetherlandsGregorio Fazzi6Dept of Pharmacology, Maastricht University, Maastricht, The NetherlandsPaul Schiffers6Dept of Pharmacology, Maastricht University, Maastricht, The NetherlandsMarc Iglarz7Actelion Pharmaceuticals Ltd, Allschwill, SwitzerlandWalter Fischli7Actelion Pharmaceuticals Ltd, Allschwill, SwitzerlandHossein Ardeschir Ghofrani1Universities of Giessen and Marburg Lung Center (UGMLC), Member of the German Center for Lung Research, Giessen, GermanyNorbert Weissmann1Universities of Giessen and Marburg Lung Center (UGMLC), Member of the German Center for Lung Research, Giessen, GermanyFriedrich Grimminger1Universities of Giessen and Marburg Lung Center (UGMLC), Member of the German Center for Lung Research, Giessen, GermanyWerner Seeger1Universities of Giessen and Marburg Lung Center (UGMLC), Member of the German Center for Lung Research, Giessen, Germany8Max-Planck-Institute for Heart and Lung Research, Member of the German Center for Lung Research, Bad Nauheim, GermanyIrwin Reiss2Division of Neonatology, Erasmus MC Sophia Children's Hospital, Rotterdam, The Netherlands9Both authors contributed equallyRalph Theo Schermuly1Universities of Giessen and Marburg Lung Center (UGMLC), Member of the German Center for Lung Research, Giessen, Germany9Both authors contributed equally
- Characterisation of an experimental mouse model of exposure to nanoparticles. Relevance to human sarcoidosisBy Serge Lebecque, Toufic Renno, Azzak Bentaher, Marine Ponchon, Alain Calender, Jean-François Bernaudin, Dominique Valeyre, Marc Iglarz, Herve Farine, Daniel Strasser and Yves PachecoSerge Lebecque1UCBLyon1, INSERM 1052/CNRS 5286, Lyon, FranceToufic Renno2UCBLyon1, INSERM 1052, Lyon, FranceAzzak Bentaher3CIRI, INSERM 1111, Pierre Benite, FranceMarine Ponchon4CIRI, INSERM 1111, Pierre Benite, FranceAlain Calender5CNRS 1462, UCBLyon1, Lyon, FranceJean-François Bernaudin6APHP, CHU Tenon, Paris, FranceDominique Valeyre7APHP, CHU Avicenne, Bobigny, FranceMarc Iglarz8Actelion Pharma, Actelion, Allschwil, SwitzerlandHerve Farine9Actelion Pharma, Actelion, Allschwil, SwitzerlandDaniel Strasser10Actelion Pharma, Actelion, Allschwil, SwazilandYves Pacheco11UCBLyon1, INSERM 1111, Pierre Benite, France
Buying books on this site
Purchases made on this website are of electronic books only.
About the ERS books
The ERS Monograph is the quarterly book series from the European Respiratory Society. Each Monograph covers a specific area of respiratory medicine, providing in-depth reviews that give clinicians at all levels a concise, comprehensive guide to symptoms, diagnosis and treatment.
The ERS Handbooks are compact guides to broad areas of the respiratory field. Launched in 2010, the series now covers adult, paediatric and sleep respiratory medicine, includes a companion volume of self-assessment questions and features the ERS Practical Handbooks.